Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Author: kodiac

Elamipretide

Our opinion on this compoundNovel, promising

69/100

First-in-class cardiolipin-binding peptide with FDA approval for Barth syndrome and genuine bench probe utility

Look, the Szeto-Schiller peptide story is one of the more interesting accidents in mitochondrial pharmacology. SS-31 was discovered while chasing opioid receptors, and what came out was something genuinely different: a synthetic tetrapeptide that ignores cytoplasm almost entirely, concentrates more than 1000-fold in the inner mitochondrial membrane, and works not as a stoichiometric antioxidant but as an electrostatic modulator of cardiolipin-containing bilayers. The Mitchell et al. 2020 biophysical work nailed the mechanism with real precision: dissociation constant of 2.0 to 2.9 micromolar for cardiolipin membranes, saturable surface potential reduction, divalent cation exclusion operating independently of membrane potential. Thats not receptor hand-waving. That’s a physical chemistry description of how the compound actually works.

The FDA accelerated approval for Barth syndrome in September 2025 under the name FORZINITY is meaningful, and we should say so plainly. Barth syndrome patients carry tafazzin gene mutations that produce structurally defective cardiolipin, which is precisely the molecular substrate where elamipretide is most directly operative. The TAZPOWER open-label extension showed cumulative 96-meter improvement in six-minute walk distance at 168 weeks (P = 0.003) plus sustained knee extensor gains. Its not a massive effect size, but in a disease with no prior approved therapy and a mechanism this well-matched to the underlying pathology, it clears the bar. The ex vivo failing human heart work is equally compelling: at 100 micromolar, elamipretide selectively restored Complex I-driven oxygen flux and respiratory control ratio in failing tissue but not in non-failing controls, a disease-selective readout you can’t get from a generic antioxidant.

What we don’t love is the broader program. MMPOWER-3 (n = 218) missed its co-primary endpoints in primary mitochondrial myopathy. Heart failure with reduced ejection fraction trials, including PROGRESS-HF and EMBRACE-STEMI, similarly didn’t meet primary endpoints. The dry AMD ReCLAIM series added another failure. The pattern that emerges is a compound that’s exquisitely suited to populations with primary cardiolipin pathology and much weaker in heterogeneous mitochondrial dysfunction. The MMPOWER post hoc finding of a responding subgroup with nuclear DNA replisome variants and CPEO phenotype is genuinely worth following, but its not confirmatory.

For investigators, the bench probe value here is substantial and somewhat independent of the clinical story. Elamipretide is currently the only tool that lets you interrogate cardiolipin-ETC supercomplex interactions in live or freshly explanted tissue without membrane disruption. If your research program touches cardiolipin remodeling, cristae architecture, or supercomplex stability, this is the compound that makes previously unanswerable questions answerable. Pharmacokinetically it’s clean: 92 percent subcutaneous bioavailability, no hepatic metabolism, no CYP interactions, short half-life, predictable dosing profile for preclinical translation.

We place this solidly in the novel-promising tier. The mechanism is first-in-class, the Barth syndrome approval gives the cardiolipin story real regulatory weight, and the bench utility is high. But repeated broad-indication failures and an accelerated rather than full approval temper the translational score. The aging skeletal muscle and CPEO subgroup programs are worth watching closely as the next legible signal.

Novelty

68

Mechanism promise

78

In-category differentiation

75

Evidence quality

58

Translational signal

62

Research bench value

70

Rationale Elamipretide holds the first-in-class cardiolipin-binding mechanism with rigorous biophysical characterization and FDA accelerated approval in Barth syndrome, but a broad clinical program that repeatedly failed primary endpoints outside that genetically defined population keeps translational and evidence scores from climbing higher; bench probe value for cardiolipin-ETC supercomplex work is independently strong.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Mitochondria-targeted aromatic-cationic tetrapeptide that binds cardiolipin in the inner mitochondrial membrane

A first-in-class cardiolipin-binding tetrapeptide developed by Szeto and Schiller that stabilizes mitochondrial cristae architecture, restores electron transport chain supercomplex function, and received FDA accelerated approval for Barth syndrome as the first mitochondria-targeted peptide therapeutic.

Abstract

Elamipretide (D-Arg-2′,6′-dimethylTyr-Lys-Phe-NH2; also designated SS-31, MTP-131, and Bendavia) is a synthetic aromatic-cationic tetrapeptide that concentrates more than 1000-fold in the inner mitochondrial membrane, where it binds cardiolipin and modulates membrane surface electrostatics to stabilize cristae architecture, optimize electron transport chain supercomplex assembly, and reduce reactive oxygen species generation at the mitochondrial source. Discovered fortuitously by Hazel Szeto and Peter Schiller during opioid receptor research, the compound was characterized in a foundational 2004 report demonstrating nanomolar-range cytoprotection against oxidative cell death and reperfusion injury in isolated mitochondria and ex vivo cardiac tissue. Biophysical studies by Mitchell et al. (2020) have since established that the primary mechanism is not stoichiometric antioxidant scavenging but rather electrostatic modulation of anionic lipid bilayer properties: SS-31 partitions into the membrane interfacial region with a dissociation constant of 2.0 to 2.9 micromolar for cardiolipin-containing membranes, saturably reduces surface potential, and decreases interfacial divalent cation accumulation by over an order of magnitude; these effects are independent of mitochondrial membrane potential. In freshly explanted failing human heart tissue, elamipretide at 100 micromolar selectively restored Complex I-driven oxygen flux, supercomplex coupling, and respiratory control ratio without affecting non-failing hearts, confirming a disease-selective mechanism operating through cardiolipin-protein interaction stabilization rather than cardiolipin remodeling. Stealth BioTherapeutics advanced elamipretide through clinical programs in Barth syndrome (TAZPOWER), primary mitochondrial myopathy (MMPOWER series), heart failure with reduced ejection fraction (PROGRESS-HF, EMBRACE-STEMI), and dry age-related macular degeneration (ReCLAIM series). The Barth syndrome program, conducted in patients with tafazzin gene mutations and defective cardiolipin remodeling, demonstrated sustained improvements in six-minute walk distance (cumulative 96.1 meters at 168 weeks, P = 0.003) and knee extensor muscle strength in the open-label extension, leading to FDA accelerated approval in September 2025 under the brand name FORZINITY for improvement of muscle strength in adult and pediatric patients weighing at least 30 kilograms. The 12-week randomized crossover portion of TAZPOWER did not meet its primary endpoints, and the pivotal Phase 3 trial in primary mitochondrial myopathy (MMPOWER-3, n = 218) did not meet co-primary endpoints on six-minute walk test and fatigue score, though post hoc analysis identified a responding subgroup with nuclear DNA replisome pathogenic variants and chronic progressive external ophthalmoplegia phenotype. Heart failure and macular degeneration trials similarly did not meet primary endpoints, though exploratory signals in cardiac volume reduction and ellipsoid zone preservation were observed. Pharmacokinetically, elamipretide is administered as a 40 mg subcutaneous injection once daily, with absolute bioavailability of approximately 92 percent, time to peak concentration of 0.5 to 1 hour, plasma elimination half-life of approximately 3 to 4 hours, and exclusively renal elimination with no hepatic metabolism and no cytochrome P450 interactions. This monograph reviews the chemistry and structure, discovery history, cardiolipin-binding pharmacology, pharmacokinetics, preclinical evidence across cardiac, renal, neuroinflammatory, and aging models, the complete clinical trial inventory across all studied indications, sourcing and quality verification, handling, drug interactions, adverse event profile, and a comparative assessment of five mitochondrial therapeutics (idebenone, omaveloxolone, MitoQ, vatiquinone, and coenzyme Q10) against elamipretide on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1641Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 22, 2026
Reldesemtiv

Our opinion on this compoundNiche research probe

60/100

Phase 3 futility in ALS leaves a well-characterized FSTA with real probe value but no clinical future

Look, reldesemtiv is one of those compounds where the science is genuinely interesting and the clinical story is genuinely disappointing. The fast skeletal muscle troponin activator class was a real idea. Sensitize the sarcomere to calcium by slowing troponin C release, get more force output from whatever motor units are still firing in a denervated muscle. That’s a clean mechanistic hypothesis, and Cytokinetics executed the chemistry well enough to confirm it in actual human tissue.

The Phase 1 pharmacodynamic work is the bright spot. Sixteen healthy volunteers, tibialis anterior force-frequency response amplified roughly 60 percent at 10 Hz stimulation. That’s not an indirect surrogate; that’s the mechanism working in human muscle. The pharmacokinetics are well-characterized across five Phase 1 studies, dose-proportional exposure, 5-14 hour half-life, similar profiles in young and elderly. If you want to study calcium sensitization in fast skeletal fibers, this compound is pharmacologically tractable and well-understood at the bench level.

The second-generation story also matters. Tirasemtiv, the first FSTA, hit dose-limiting dizziness, nausea, weight loss, and insomnia hard enough that 34.2 percent of VITALITY-ALS participants discontinued. Reldesemtiv represents property-based optimization that genuinely improved tolerability. Thats a real accomplishment even if it didn’t change the terminal clinical outcome. The selectivity profile is also authentic: no activation of slow skeletal or cardiac troponin complexes, which is exactly what you want from a probe compound designed to isolate fast-fiber effects.

But COURAGE-ALS happened. Phase 3, 486 patients, 83 centers across 16 countries, 24 weeks. Conditional power at the second interim analysis: 8.4 percent. The primary ALSFRS-R endpoint numerically favored placebo. No preplanned subgroup favored reldesemtiv. The program was terminated for futility. That’s not ambiguous. The translational hypothesis that calcium sensitization of residual fast fibers would slow functional decline in ALS did not survive a rigorous test. The FORTITUDE-ALS Phase 2 miss on slow vital capacity (p=0.11) was a warning sign; COURAGE-ALS confirmed it.

The SMA Phase 2 data is more interesting and prevents a complete write-off. Seventy patients, statistically significant improvement in six-minute walk distance at week 4 (35.6 m, p=0.0037) and maximum expiratory pressure at week 8 in the 450 mg group. The neuronal-attenuation hypothesis may hold better in SMA than ALS for reasons related to the pattern of motor neuron loss and the stage at which fast-fiber populations are still available to sensitize. Whether that Phase 2 signal survives a larger trial is genuinely unknown.

What we think: reldesemtiv earns real points for mechanism novelty, fast-fiber selectivity, and the quality of its clinical evidence base, even though that evidence base ultimately killed the program. It’s now probe territory. For investigators studying calcium handling in fast skeletal muscle, motor unit physiology, or the FSTA class itself, this is the best-characterized compound available. The WADA listing confirms sourcing exists. Score it for what it is now: a well-made tool with a closed clinical chapter.

Novelty

62

Mechanism promise

68

In-category differentiation

65

Evidence quality

65

Translational signal

38

Research bench value

58

Rationale Reldesemtiv scores well on mechanism novelty and fast-fiber selectivity but takes a decisive translational hit from COURAGE-ALS, where conditional power fell to 8.4 percent and the primary endpoint numerically favored placebo; the SMA Phase 2 signal and clean pharmacological profile sustain moderate bench utility. Category placement as niche-probe reflects a terminated clinical program that left behind the best-available FSTA tool compound for fast skeletal muscle calcium biology.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Second-generation fast skeletal muscle troponin activator (FSTA) selective for fast skeletal muscle fibers

A next-generation fast skeletal muscle troponin activator developed by Cytokinetics to amplify skeletal muscle force output through calcium sensitization of the sarcomere, evaluated in Phase 2 and Phase 3 clinical trials in amyotrophic lateral sclerosis and spinal muscular atrophy.

Abstract

Reldesemtiv (CK-2127107) is a small-molecule fast skeletal muscle troponin activator (FSTA) that selectively binds the regulatory troponin complex in fast skeletal muscle fibers, slows the rate of calcium release from troponin C, and thereby sensitizes the sarcomere to calcium at submaximal stimulation frequencies. The compound was discovered at Cytokinetics, Inc. through property-based optimization of a high-throughput screening hit, yielding improved free exposure, in vivo muscle activation potency, and tolerability relative to the first-generation FSTA tirasemtiv, which had failed the Phase 3 VITALITY-ALS trial primarily because of dose-limiting tolerability (dizziness, nausea, weight loss, insomnia) and a 34.2 percent treatment discontinuation rate. Reldesemtiv does not activate slow skeletal or cardiac troponin complexes, providing a selectivity basis for its intended use in conditions characterized by fast skeletal muscle weakness secondary to attenuated neuronal input, including amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and chronic obstructive pulmonary disease. In a Phase 1 pharmacodynamic study in 16 healthy volunteers, reldesemtiv amplified the tibialis anterior force-frequency response by approximately 60 percent at 10 Hz nerve stimulation at the highest plasma concentrations tested, confirming the mechanism of action in human skeletal muscle. Pharmacokinetics across five Phase 1 studies demonstrated dose-proportional exposure with a terminal half-life of approximately 5 to 14 hours depending on dose, a time to peak concentration of 2 to 3 hours, and similar pharmacokinetic profiles in young and elderly subjects. The Phase 2 FORTITUDE-ALS trial (n=458; 12 weeks; placebo, 150, 300, or 450 mg twice daily) did not reach statistical significance on its primary endpoint of slow vital capacity change (p=0.11), though trends favoring reldesemtiv were observed across all three endpoints and a post hoc analysis of the ALSFRS-R functional scale reached nominal significance (p=0.01). The Phase 2 SMA study (n=70; 8 weeks; 150 or 450 mg twice daily) reported statistically significant improvement in six-minute walk distance at week 4 (35.6 m, p=0.0037) and maximum expiratory pressure at week 8 (13.2 cmH2O, p=0.03) in the 450 mg group, with concentration-response relationships in the highest plasma concentration quartile reaching significance on both endpoints. The Phase 3 COURAGE-ALS trial (n=486; 24 weeks; 300 mg twice daily versus placebo; 83 centers in 16 countries) was terminated for futility at the second planned interim analysis when conditional power for the primary endpoint (ALSFRS-R score change at 24 weeks) was 8.4 percent. The primary analysis showed a mean difference of negative 1.1 points (95 percent CI, negative 2.17 to negative 0.08; p=0.04), numerically favoring placebo. No preplanned subgroup favored reldesemtiv. The compound is not approved by any regulatory authority for any indication. This monograph reviews the chemistry, discovery, molecular pharmacology, pharmacokinetics, preclinical and clinical evidence, sourcing, handling, adverse events, and a comparative assessment of reldesemtiv against tirasemtiv, tofersen, riluzole, edaravone, and risdiplam on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1658Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 22, 2026
Danavorexton

Our opinion on this compoundNovel frontier

72/100

First-in-class small-molecule OX2R agonist with extraordinary Phase 1 human signal, constrained by IV route and advancing oral successors

Look, danavorexton earns its place at the frontier in a way that few investigational compounds do: its the first nonpeptide small-molecule orexin 2 receptor agonist to generate human clinical proof-of-concept, and the effect sizes in narcolepsy type 1 are striking enough that they essentially validated the orexin replacement hypothesis in a single Phase 1 program. That matters for how we think about this class.

The chemistry story is genuinely interesting on its own. Takeda’s medicinal chemistry campaign converted a micromolar hit (EC50 570 nM) into a low-nanomolar agonist (EC50 5.5 nM) with greater than 18,000-fold selectivity for OX2R over OX1R. Selectivity that extreme in a receptor pair this structurally similar is mechanistically meaningful, and the cryo-EM structures of the OX2R-G protein complex at 3.2 to 3.3 angstrom resolution show exactly why: two residue differences at positions 2.61 and 3.33 create steric and desolvation disparities that danavorexton exploits through a compact U-shaped conformation and a critical sulfonamide-Gln134 hydrogen bond. That structural resolution is a research contribution independent of the therapeutic story, and it makes danavorexton a useful anchor compound for anyone building OX2R pharmacophore models.

What we find most compelling is the translational signal. In NCT03748979, narcolepsy type 1 participants maxed out the Maintenance of Wakefulness Test ceiling (40 minutes across all sessions), reduced cataplexy episodes to zero during infusion, and normalized Epworth Sleepiness Scale scores from 18.6 to 0.0 by day 7. Placebo-adjusted sleep latency improvement of 29.4 minutes in idiopathic hypersomnia. Reversal of remifentanil-induced respiratory depression (minute volume increase of 13.0 L/min, p less than 0.001) without reversing analgesia. These arent modest signals; the mechanism-to-effect arrow here is unusually clean.

The honest limitation is the route. Intravenous infusion over nine hours is a proof-of-concept instrument, not a clinical product. Takedas program knew this: TAK-994 demonstrated even stronger oral efficacy but was discontinued after three Hy’s law hepatotoxicity cases, and TAK-861 (oveporexton) is now advancing toward Phase 3 registration with no hepatic signal. Danavorexton’s therapeutic path is effectively closed. What remains is its value as the most pharmacologically characterized OX2R agonist in the literature, with six registered clinical studies, a cryo-EM resolved structure, and unusually clean PK-PD data from controlled IV administration.

For investigators working on sleep circuitry, orexin-system biology, opioid-respiratory crosstalk, or GPCR structural pharmacology, this compound is a legitimate and well-validated research tool. Evidence is Phase 1-weight, which is why overall doesn’t reach the high seventies, but the novelty of the structural class and the magnitude of the human signal place it solidly in frontier territory.

Novelty

70

Mechanism promise

75

In-category differentiation

72

Evidence quality

58

Translational signal

80

Research bench value

75

Rationale Scores are driven upward by a genuinely paradigm-defining translational signal in Phase 1 narcolepsy and idiopathic hypersomnia studies, novel structural biology (first cryo-EM OX2R agonist complex resolved at 3.2 Å), and first-in-class status as the only small-molecule OX2R agonist with clinical proof of concept. Evidence and differentiation scores are held back by Phase 1-only weight and the reality that oral successors have already moved the field past this specific molecule as a therapeutic candidate.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective orexin 2 receptor agonist (nonpeptide, intravenous piperidine carbamate)

A selective nonpeptide orexin 2 receptor agonist developed at Takeda Pharmaceutical Company, the first small-molecule OX2R agonist to achieve clinical proof of concept for orexin replacement therapy across narcolepsy type 1 and type 2, idiopathic hypersomnia, obstructive sleep apnea, and opioid-induced respiratory depression.

Abstract

Danavorexton (TAK-925) is a potent, selective, brain-penetrant, nonpeptide orexin 2 receptor (OX2R) agonist developed by Takeda Pharmaceutical Company as the first small-molecule orexin receptor agonist to enter clinical development. Identified through high-throughput screening and optimized through a medicinal chemistry campaign that converted a micromolar-potency hit (EC50 570 nM) into a low-nanomolar agonist (EC50 5.5 nM in calcium mobilization assays) with greater than 18,000-fold selectivity for human OX2R over OX1R, danavorexton is a (2R,3S)-piperidine carbamate bearing a cis-4-phenylcyclohexyl ether and a methylsulfonamide pharmacophore. The compound adopts a compact U-shaped conformation that engages the OX2R orthosteric pocket through a critical hydrogen bond between the sulfonamide nitrogen and Gln134(3.32), as resolved by two cryo-electron microscopy structures of the OX2R-G protein complex at 3.2 to 3.3 angstrom resolution. Selectivity over OX1R arises from subtle differences at only two residues (Thr111(2.61) and Thr135(3.33) in OX2R versus Ser and Ala at the corresponding positions in OX1R) that alter steric complementarity and desolvation within the orthosteric pocket. Administered exclusively by intravenous infusion, danavorexton has completed Phase 1 clinical studies in narcolepsy type 1, narcolepsy type 2, idiopathic hypersomnia, obstructive sleep apnea with residual excessive daytime sleepiness, and opioid-induced respiratory depression, collectively enrolling over 150 participants across six registered trials. In a multiple-rising-dose study (NCT03748979), danavorexton at 44 mg intravenous over 9 hours produced maximal Maintenance of Wakefulness Test sleep latency (40 minutes in all sessions) in all narcolepsy type 1 participants, reduced cataplexy episodes to zero during infusion, and normalized the Epworth Sleepiness Scale score from a baseline of 18.6 to 0.0 by day 7. Comparable wakefulness-promoting effects were demonstrated in narcolepsy type 2, idiopathic hypersomnia (placebo-adjusted sleep latency improvement of 29.4 minutes), and sleep-deprived healthy volunteers (sleep latency of 31.8 minutes at 112 mg versus 9.2 minutes on placebo). In a crossover study of remifentanil-induced respiratory depression, danavorexton reversed respiratory depression (minute volume increase of 13.0 L/min at 19 mg, p < 0.001) and sedation without reversing opioid analgesia. Human pharmacokinetics are characterized by dose-proportional plasma concentrations, a terminal half-life of approximately 3 to 5 hours, negligible accumulation with daily 9-hour infusions, and a cerebrospinal fluid-to-plasma concentration ratio of approximately 2.8 percent. The compound is well tolerated across all studied populations. The most common drug-related adverse events are pollakiuria (urinary frequency), transient blood pressure elevation, insomnia, headache, and dizziness, all predominantly mild in severity. No hepatotoxicity has been observed, distinguishing danavorexton from its oral successor TAK-994 (firazorexton), which demonstrated exceptional efficacy in a Phase 2 narcolepsy trial but was discontinued following drug-induced liver injury in three participants meeting Hy's law criteria. The second-generation oral OX2R agonist TAK-861 (oveporexton), structurally distinct from both danavorexton and TAK-994, has completed a positive Phase 2 trial with no hepatic signal and is advancing toward Phase 3 registration. This monograph reviews the medicinal chemistry, structural biology, receptor pharmacology, pharmacokinetics, preclinical and clinical evidence base, adverse event profile, sourcing and handling considerations, and a comparative assessment of danavorexton against four alternative agents in the narcolepsy and excessive daytime sleepiness pharmacotherapy space (TAK-994, TAK-861, pitolisant, solriamfetol) on five competency standards. Danavorexton is not approved for any indication in any jurisdiction. It is an investigational compound available in research-grade preparations; investigators should obtain analytical confirmation of identity and purity on every lot.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1647Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 22, 2026
CMS121

Our opinion on this compoundNovel, promising

60/100

Salk-derived FASN inhibitor with Phase 1 PK data and coherent multi-model neuroprotective preclinical signal

CMS121 came out of a serious medicinal chemistry campaign: over 160 synthetic fisetin derivatives screened at the Salk Institute for Biological Studies, not for receptor binding but for functional neuroprotection in HT22 hippocampal cells under glutamate and iodoacetic acid toxicity. That’s phenotypic screening done properly. The compound that emerged had nanomolar protective activity, oral bioavailability, and anti-inflammatory activity the parent flavonoid lacked. It was then dosed in mice for years before anyone went looking for the target. The Ates et al. 2020 Redox Biology paper identifying fatty acid synthase as the molecular anchor is a real mechanistic result, not a mechanism-by-assertion story you see too often in this space.

What we like is the mechanistic coherence downstream of FASN. Inhibit the enzyme, reduce polyunsaturated fatty acid availability, cut the ferroptotic lipid peroxidation signal, lower 4-HNE adducts, suppress iNOS and COX-2 in microglia. That’s a clean causal chain to an increasingly important cell death pathway in neurodegeneration. But the Currais et al. eLife 2019 paper adds a layer most anti-ferroptotic compounds can’t claim: elevated acetyl-CoA feeds histone H3K9 acetylation in SAMP8 mice, and that epigenetic angle tracks with preserved cognition. Connecting lipid metabolism to chromatin state in the aging brain is not a well-trodden route, and honestly thats what makes CMS121 interesting as a research tool beyond its therapeutic ambitions.

The preclinical width is real. APPswe/PS1deltaE9 AD mice, SAMP8 accelerated aging, R6/2 and YAC128 Huntington’s models, db/db metabolic mice. Cross-indication breadth like that either means the mechanism is genuinely fundamental to age-associated cell stress or the lab is skilled at finding what it’s looking for. The HD lifespan extension data, up to 17 percent in R6/2, is hard to dismiss. What it isn’t is independently replicated. Almost all of this literature traces back to the Maher and Schubert group at Salk. Thats one consortium, and the calibration anchors say that matters.

The Phase 1 (NCT05318040, 88 healthy volunteers, single ascending doses to 1800 mg, multiple ascending doses to 900 mg/day for seven days) moved things forward in a specific way. CMS121 reaches systemic circulation in humans, tolerability was generally acceptable, PK was dose-proportional or slightly supraproportional, and the CMS121-C2 metabolite dominates circulating exposure, which has implications for what’s actually doing the work in vivo. Elderly subjects showed higher exposure and longer half-life than young adults. That’s a lot to know at Phase 1. What it is not is efficacy data. Zero human cognitive or biomarker signal has been reported.

For bench investigators, the probe case is specific: if you want to study ferroptosis in neural or aging contexts with a drug-like, orally bioavailable FASN inhibitor, CMS121 fills a niche that ferrostatin-1 can’t because of its PK and that denifanstat (TVB-2640) wasn’t designed for given its oncology orientation. The FASN/acetyl-CoA/histone axis tool value is genuine. We think this is worth following, particularly if Phase 2 efficacy trials move forward. Right now it’s a well-built compound with an interesting story and one lab telling it.

Novelty

72

Mechanism promise

75

In-category differentiation

62

Evidence quality

42

Translational signal

38

Research bench value

65

Rationale CMS121 earns its score on genuine mechanistic novelty: FASN inhibition driving ferroptosis suppression and histone H3K9 acetylation is an unusual and internally coherent story, and the Phase 1 completion elevates it above pure single-lab status. The ceiling is the Salk/Maher group’s near-monopoly on the literature and the complete absence of human efficacy data.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Geroneuroprotective small molecule; synthetic fisetin derivative; fatty acid synthase inhibitor with anti-ferroptotic and anti-inflammatory activity

A synthetic quinoline derivative of the flavonoid fisetin, developed at the Salk Institute through phenotypic screening against age-associated neuronal cell death, that inhibits fatty acid synthase and acetyl-CoA carboxylase 1 to protect against ferroptotic lipid peroxidation and cognitive decline in transgenic Alzheimer’s disease and accelerated aging mouse models, with Phase 1 human pharmacokinetic data completed in 2022.

Abstract

CMS121 (CAS 1353224-53-9) is a synthetic quinoline derivative of the dietary flavonoid fisetin (3,7,3′,4′-tetrahydroxyflavone), identified through a phenotypic screening cascade at the Salk Institute for Biological Studies as a potent inhibitor of oxytotic/ferroptotic neuronal cell death with nanomolar protective activity in glutamate toxicity and iodoacetic acid toxicity assays in the HT22 hippocampal cell line. The compound was selected from more than 160 synthetic fisetin derivatives prepared by Chiruta, Schubert, Dargusch, and Maher (Journal of Medicinal Chemistry, 2012) through a multitiered screening approach that evaluated neuroprotective potency, anti-inflammatory activity, and oral pharmacokinetic suitability. The molecular target of CMS121 was subsequently identified as fatty acid synthase (FASN), with dose-dependent enzymatic inhibition demonstrated in cell lysate assays (Ates, Goldberg, Currais, and Maher, Redox Biology, 2020). Downstream of FASN inhibition, CMS121 engages the AMP-activated protein kinase/acetyl-CoA carboxylase 1 (AMPK/ACC1) axis, elevating intracellular acetyl-CoA levels and promoting histone H3 lysine 9 acetylation, a modification linked to memory enhancement in the senescence-accelerated mouse prone 8 (SAMP8) model (Currais et al., eLife, 2019). The anti-ferroptotic mechanism operates through reduction of polyunsaturated fatty acid substrates available for lipid peroxidation, thereby decreasing 4-hydroxynonenal protein adduct accumulation and suppressing downstream neuroinflammatory cascades including inducible nitric oxide synthase, cyclooxygenase-2, and tumor necrosis factor-alpha expression in activated microglia. Preclinical efficacy has been demonstrated across multiple disease models: in APPswe/PS1deltaE9 double transgenic Alzheimer’s disease mice, dietary CMS121 at 400 parts per million (approximately 34 mg/kg/day) for three months beginning at nine months of age normalized spatial memory, contextual fear conditioning, and hippocampal lipid peroxidation markers to wild-type levels; in SAMP8 accelerated aging mice, four months of treatment preserved cognition and reduced transcriptional markers of brain aging; in R6/2 and YAC128 Huntington’s disease models, CMS121 slowed motor dysfunction and extended median lifespan by up to 17 percent; and in db/db leptin receptor deficient mice and wild-type C57BL/6 mice, the compound ameliorated metabolic dysfunction, reduced adiposity, and improved hepatic and renal biomarkers. The compound was advanced to a first-in-human Phase 1 clinical trial (NCT05318040) by Virogenics, Inc. in collaboration with the National Institute on Aging, conducted at Celerion (Lincoln, Nebraska) in 2022. Single ascending doses up to 1800 mg and multiple ascending doses up to 900 mg per day for seven days were generally well tolerated in approximately 88 healthy volunteers, with the majority of treatment-emergent adverse events mild in severity. Pharmacokinetics were dose-proportional or slightly greater than dose-proportional; the CMS121-C2 metabolite was the predominant circulating species; urinary excretion was minimal; systemic exposure was approximately 50 percent higher in the fed state; and elderly subjects exhibited higher exposures and longer terminal elimination half-lives than young adults (Maher, Christopher, Evans, and Raschke, medRxiv, 2025, preprint). This monograph reviews the chemistry and structural relationship to fisetin; the FASN/ACC1/AMPK molecular pharmacology; the preclinical evidence base across Alzheimer’s disease, Huntington’s disease, aging, and metabolic models; the Phase 1 human pharmacokinetic and safety data; sourcing and handling considerations for research applications; and a comparative assessment of five related compounds (fisetin, J147, CAD031, denifanstat, and ferrostatin-1) against CMS121 on five competency standards. The compound has not received regulatory approval for any therapeutic indication. It is positioned as a research-grade geroneuroprotector for investigational use.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1642Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 22, 2026
NPT520-34

Our opinion on this compoundNovel, promising

64/100

First-in-class oral TLR2 antagonist breaking alpha-synuclein feedforward loop, strong mechanism, no patient data yet

Honestly, NPT520-34 is one of the more conceptually interesting compounds we’ve reviewed in the neurodegeneration space. The core story is a feedforward loop that’s been building in the Parkinson’s literature for years: oligomeric alpha-synuclein activates TLR2 on microglia and neurons, TLR2 activation suppresses autophagy through the AKT/mTOR axis, which lets alpha-synuclein accumulate further, which drives more TLR2 signaling. Neuropore’s compound interrupts that cycle at the TLR2 node. That’s not a trivial target choice. Postmortem PD brain data shows TLR2 neuronal expression climbing from roughly 3 percent in control tissue to 47 percent in late-stage disease, which is the kind of biological anchor that justifies building a selective antagonist for it. The dual pharmacology is genuinely elegant: you clear the aggregates and suppress the inflammation from the same single target.

The preclinical package in the mThy1-alpha-synuclein Line 61 transgenic model is solid for a small-molecule CNS program. Daily dosing at 0.5 to 10 mg/kg produced dose-dependent reductions in total alpha-synuclein in the neocortex (P less than 0.0001 at the higher doses), reductions in proteinase K-resistant synuclein in the striatum, and functional improvements in grip strength and gait analysis. The acute LPS-challenge data showing suppression of IL-6, TNF-alpha, and MIP-2 adds to the anti-inflammatory story. Mouse PK confirms brain penetrance in a dose-linear fashion, and the oral bioavailability is essential for any realistic chronic neurodegeneration program.

Phase 1 (NCT03954600) enrolled 49 healthy volunteers across single and multiple ascending doses up to 500 mg/day for 14 days. Dose-linear PK, half-life around 8 hours, no serious adverse events, headache as the primary complaint. That’s a clean safety readout. The FDA orphan designation for ALS in August 2019 signals regulators found the mechanistic rationale credible. But we have to be honest about where the evidence stops: the Phase 1 data remains unpublished in a peer-reviewed journal, theres no registered Phase 2 in PD or ALS patients, and essentially all the preclinical data comes from within the Neuropore program itself. The Line 61 model is well-regarded as a synuclein overexpression tool, but transgenic PD models have a stubborn history of poor clinical translation.

What we like here is the mechanism specificity and the oral brain-penetrant profile. As a research tool for TLR2-mediated neuroinflammation in synucleinopathy models, this is genuinely useful in a way that most peptide candidates are not. The comparison field is worth noting: anle138b is still preclinical-only, prasinezumab showed signal only in fast-progressors, nilotinib essentially failed its PD trials. NPT520-34 occupies a distinct mechanistic lane. What we dont like is the development pause. No public Phase 2 timeline, a silent publication record on the clinical data, and without patient efficacy numbers the translational signal stays entirely mechanistic. Promising first-in-class compound, real questions about whether anyone is still actively pushing it forward.

Novelty

75

Mechanism promise

78

In-category differentiation

74

Evidence quality

42

Translational signal

40

Research bench value

62

Rationale High novelty and mechanism scores reflect first-in-class TLR2 antagonism with a well-defined feedforward-loop rationale and confirmed oral CNS penetrance; evidence and translational scores are capped by single-consortium preclinical data, unpublished Phase 1 results, and a complete absence of Phase 2 patient efficacy data.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Orally bioavailable, brain-penetrant small molecule toll-like receptor 2 (TLR2) antagonist with dual activity promoting autophagic clearance of alpha-synuclein aggregates and attenuating neuroinflammation

A first-in-class small molecule TLR2 antagonist developed by Neuropore Therapies for Parkinson’s disease and amyotrophic lateral sclerosis, acting through dual suppression of neuroinflammation and enhancement of autophagic protein clearance in neurodegenerative synucleinopathies.

Abstract

NPT520-34 is an orally bioavailable, brain-penetrant small molecule antagonist of toll-like receptor 2 (TLR2), developed by Neuropore Therapies, Inc. (San Diego, California) as a disease-modifying therapeutic candidate for Parkinson’s disease and amyotrophic lateral sclerosis. The compound was identified through cell-based assays of alpha-synuclein clearance and subsequently characterized for two complementary pharmacological actions: enhancement of autophagic clearance of neurotoxic protein aggregates and direct attenuation of neuroinflammation mediated by microglia and astrocytes [1]. The mechanistic rationale targets TLR2, a pattern-recognition receptor of the innate immune system that is upregulated approximately twofold in postmortem Parkinson’s disease brain tissue, with neuronal TLR2 expression increasing from approximately 3 percent of neurons in control brain to 47 percent in late-stage disease [3]. Neuron-released oligomeric alpha-synuclein acts as an endogenous agonist of TLR2, driving a feedforward loop of TLR2 activation, AKT/mTOR-dependent autophagy inhibition, alpha-synuclein accumulation, and neuroinflammatory cytokine release [2, 4]. NPT520-34 is proposed to interrupt this cycle through TLR2 antagonism. In the principal preclinical study, daily intraperitoneal administration of NPT520-34 at 0.5 to 10 mg/kg to mThy1-alpha-synuclein (Line 61) transgenic mice for one or three months produced statistically significant reductions in total alpha-synuclein in the neocortex (P < 0.0001 at 5 and 10 mg/kg), reductions in proteinase K-resistant alpha-synuclein in the striatum (P < 0.05 at 1, 5, and 10 mg/kg), and reductions in the neuroinflammation markers TSPO and TLR2 mRNA, with concurrent improvements in grip strength (P < 0.001 to P < 0.0001), forelimb clasping, and computerized gait analysis parameters [1]. In a separate acute lipopolysaccharide-challenge model, a single dose of NPT520-34 reduced plasma levels of pro-inflammatory cytokines including interleukin-6, tumor necrosis factor alpha, and macrophage inflammatory protein 2 [1]. In vitro, NPT520-34 increased LC3 puncta accumulation in B103 neuroblastoma cells at concentrations of 1 to 10 micromolar, consistent with autophagy induction [1]. Mouse pharmacokinetic studies demonstrated dose-dependent linear exposures in both plasma and brain tissue, confirming blood-brain barrier penetration [1]. In a Phase 1 randomized, double-blind, placebo-controlled trial (NCT03954600) enrolling 49 healthy adult volunteers, single ascending oral doses from 125 to 1000 mg and multiple ascending doses of 250 to 500 mg daily for 14 days demonstrated dose-linear pharmacokinetics with an elimination half-life of approximately 8 hours [7, 9, 11]. NPT520-34 was safe and well tolerated at all doses tested, with no serious adverse events, no discontinuations, and headache as the most frequently reported adverse event [9, 11]. The U.S. Food and Drug Administration granted orphan drug designation for the treatment of amyotrophic lateral sclerosis in August 2019 [10]. As of the date of this monograph, no Phase 2 trials in patients with Parkinson's disease or amyotrophic lateral sclerosis have been registered, and peer-reviewed publication of the Phase 1 pharmacokinetic and safety data remains pending. Investigators should treat the available clinical data as preliminary. This monograph reviews the chemistry, the TLR2-mediated mechanism of action in the context of the broader synucleinopathy literature, the preclinical pharmacology across neurodegenerative disease models, the Phase 1 clinical data, and a comparative assessment of five alternative alpha-synuclein-targeting therapeutic candidates. The compound is not approved for any indication in any jurisdiction and is available only for research use.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1651Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 22, 2026
Traxoprodil

Our opinion on this compoundNiche research probe

57/100

Discontinued NR2B-selective NMDA probe with real depression signal and hERG-terminated development

Look, traxoprodil is one of those compounds where the clinical story rivals the pharmacology. The NR2B-selective NMDA narrative starts with ifenprodil, which had the right target but came bundled with alpha-1 adrenergic activity that muddied any clean mechanistic read. Pfizer’s Central Research group fixed that with CP-101,606 in the mid-1990s: a substituted 4-phenylpiperidine binding the NR1/NR2B amino-terminal domain interface at 4.2 nM KD with no meaningful alpha-1 contamination, making it the first pharmacologically clean NR2B-selective compound to enter large-scale clinical testing.

What we find genuinely interesting is that the mechanism isn’t just “NR2B antagonism.” The proton-enhancing route Mott et al. characterized in 1998 places traxoprodil in a formally distinct class from channel blockers like ketamine and memantine: it enhances tonic proton inhibition at the receptor’s amino-terminal domain interface rather than physically occluding the channel. Whether that distinction produces meaningfully different in vivo pharmacology is still an open experimental question, and open questions are exactly where bench value lives.

The depression data is the real headline. A double-blind RCT in 30 paroxetine nonresponders showed 60% response on the Hamilton scale after a single IV infusion versus 20% on placebo, 78% of responders still responding at one week, and without meaningful dissociation. That data predates the esketamine approvals by years, and it remains one of the cleaner empirical arguments for the idea that NR2B selectivity can deliver rapid antidepressant effects without ketamine-class liability. Small trial, never replicated at scale, but the effect size is hard to wave off.

The TBI Phase 2/3 trial (n=404) trended the right way but missed significance: 7.5% improvement on dichotomized Glasgow Outcome Scale at p=0.07, 7% mortality reduction at p=0.08. Encouraging, not decisive.

Development stopped on hERG. QTc prolongation from hERG channel inhibition was judged a fundamental scaffold liability at Pfizer. Thats a safety chemistry failure, not a mechanism failure. The NR2B hypothesis remained intact after the program ended.

For bench use, traxoprodil is most useful as a clean NR2B probe where the proton-enhancing mechanism and absent alpha-1 activity let you isolate subunit-selective contributions in preparations that ketamine would confound. Ro 25-6981 competes on selectivity; rislenemdaz has a more recent clinical package; but traxoprodil carries the most complete human pharmacokinetic characterization in its class and the only functioning depression RCT among selective NR2B antagonists. The CYP2D6 phenotype is a genuine experimental variable in any in vivo design: half-life swings from 2-4 hours in extensive metabolizers to roughly 20 hours in poor metabolizers. Build that into your design explicitly or the results wont be interpretable.

Novelty

48

Mechanism promise

68

In-category differentiation

52

Evidence quality

57

Translational signal

58

Research bench value

62

Rationale Traxoprodil scores primarily on mechanism elegance (proton-enhancing versus channel-blocking distinction) and a small but striking depression RCT; penalized by small trial sizes, lack of replication, and a safety-driven development halt that left the human evidence base permanently incomplete.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

NR2B subunit-selective N-methyl-D-aspartate receptor antagonist

A second-generation phenylethanol amine ifenprodil derivative developed at Pfizer as a forebrain-selective neuroprotectant, distinguished from first-generation NR2B antagonists by absence of alpha-1 adrenergic receptor activity and clinically evaluated in traumatic brain injury, treatment-resistant major depression, and levodopa-induced dyskinesia in Parkinson’s disease.

Abstract

Traxoprodil (CP-101,606) is a potent and selective antagonist of N-methyl-D-aspartate (NMDA) receptors containing the NR2B (GluN2B) subunit, originally synthesized at the Central Research Division of Pfizer Inc. in Groton, Connecticut, and first disclosed by Chenard et al. in 1995 as a neuroprotectant with high selectivity for forebrain neurons. Structurally a substituted 4-phenylpiperidine and single-isomer phenylethanol amine derivative of the first-generation NR2B antagonist ifenprodil, traxoprodil retains the high-affinity NR2B binding (KD of 4.2 nanomolar in adult rodent forebrain) while eliminating the alpha-1 adrenergic receptor activity that limited the clinical utility of its predecessor. The compound binds at the amino-terminal domain interface of the NR1/NR2B heterodimer and inhibits channel opening by enhancing tonic proton inhibition, a mechanism formally characterized by Mott et al. (1998) that distinguishes the phenylethanol amine class from channel-blocking NMDA antagonists such as ketamine and memantine. Pharmacokinetics in humans are dominated by hepatic cytochrome P450 2D6 (CYP2D6) metabolism, producing a striking polymorphic phenotype: in CYP2D6 extensive metabolizers, the oral bioavailability at a 100 mg dose is approximately 39.5 percent with a plasma elimination half-life of 2 to 4 hours, whereas in poor metabolizers the bioavailability approaches 80 percent with a half-life of approximately 20 hours. The nonlinear, dose-dependent oral pharmacokinetics in extensive metabolizers reflect saturation of hepatic first-pass CYP2D6 metabolism; at high oral doses the impact of CYP2D6 polymorphism on exposure diminishes as the enzyme saturates. The compound was advanced through three principal clinical programs. In traumatic brain injury, an open-label study of 30 patients with severe head injury or spontaneous intracerebral hemorrhage demonstrated safety, tolerability, and 80 percent good recovery at 3 months; a subsequent randomized, double-blind, placebo-controlled Phase 2/3 trial of 404 severe TBI patients showed trends toward improved functional outcome (7.5 percent improvement on the dichotomized Glasgow Outcome Scale, p = 0.07) and reduced mortality (7 percent difference, p = 0.08) but did not reach conventional statistical significance. In treatment-resistant major depression, a randomized, double-blind, placebo-controlled proof-of-concept trial of 30 paroxetine-nonresponders demonstrated a 60 percent response rate on the Hamilton Depression Rating Scale after a single intravenous infusion of CP-101,606 versus 20 percent on placebo, with 78 percent of responders maintaining response for at least one week, and without dissociative side effects. In Parkinson’s disease, a double-blind crossover trial in 12 patients showed approximately 30 percent reduction in levodopa-induced dyskinesia but dose-dependent dissociative and amnestic adverse events. Clinical development was ultimately discontinued due to cardiovascular safety concerns, specifically QTc interval prolongation attributed to inhibition of the human ether-a-go-go-related gene (hERG) potassium channel, a liability that Pfizer determined precluded further advancement. This monograph reviews the chemistry and stereochemistry of traxoprodil; the NR2B-selective pharmacology including the proton-enhancing mechanism and the two-class distinction among NR2B antagonists; the comprehensive CYP2D6-dependent human pharmacokinetics; the preclinical neuroprotection, antinociception, antiparkinsonian, and antidepressant pharmacology; the clinical evidence across traumatic brain injury, treatment-resistant depression, and Parkinson’s disease; and a comparative assessment of five NR2B-selective or NMDA-targeting compounds (rislenemdaz, ifenprodil, Ro 25-6981, radiprodil, and ketamine) against traxoprodil on five competency standards. The compound is not approved by any regulatory authority for any indication. It is available as a research-grade preparation; investigators should obtain analytical confirmation of identity and purity on every lot.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1646Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 22, 2026
Navacaprant

Our opinion on this compoundNovel, promising

63/100

Cleanest KOR antagonist in clinical testing, real anhedonia signal, but Phase 3 null is hard to explain away

Look, the kappa opioid receptor story for depression is genuinely interesting biology, and navacaprant is the cleanest version of the hypothesis we’ve seen in a clinical setting. The KOR system is deeply wired into stress circuits, anhedonia, and dysphoria. Blocking it isn’t just another monoamine trick; it’s targeting a specific neurobiological substrate that standard antidepressants don’t touch. That mechanistic angle is real, and the compound’s selectivity profile makes it the best available probe for it.

The pharmacology is unusually clean. 1.2 nM potency at KOR in native VTA dopamine neurons, 300-fold selectivity over mu, 340-fold over delta, no detectable agonist activity at any opioid subtype in vitro. The problems that killed JDTic (c-JNK activation, cardiac toxicity in humans), made nor-BNI impractical (weeks-long receptor occupancy), and muddied aticaprant’s mechanism (partial mu/delta activity in native tissue electrophysiology) simply don’t apply here. The PET occupancy work is also genuinely useful: a single 160 mg dose achieving roughly 90 percent KOR occupancy, with the 80 mg clinical dose projected to maintain that at steady state. That kind of pharmacokinetic-pharmacodynamic clarity is exactly what you want in a research probe.

Here’s the thing though. The clinical picture is complicated. The Phase 2a data from Mathew et al. 2025 has a real signal buried in it: in the moderate-to-severe MDD subgroup, response rates were 45.5 percent versus 24.1 percent for placebo, and an NNT of 5 for response is genuinely meaningful. Anhedonia-specific improvements on the SHAPS are mechanistically consistent with what you’d predict from KOR blockade. But the primary endpoint failed. And then KOASTAL-1 failed badly: both arms reported identical 12.5-point MADRS reductions, p equals 0.993. Thats not a near-miss, that’s a null, and a large-N null at that.

We think the compound is probably doing something real in a specific subpopulation, and the failure mode is patient selection rather than mechanism failure. The exploratory differential response in female participants in KOASTAL-1 and the protocol modifications for KOASTAL-2 and KOASTAL-3 suggest Neumora’s team agrees. Whether that stratification story holds up in 2026 matters enormously for any translational read. For now, the human evidence is inconsistent enough that we score it conservatively.

What we still like: navacaprant is the only available selective reversible KOR antagonist with Phase 3-grade pharmacokinetic characterization and confirmed brain penetrance in humans. For anyone studying stress-induced anhedonia models, dynorphin signaling, or KOR circuit biology in affective states, this is the probe you’d reach for over any alternative. The tolerability profile is also a research asset: no weight gain, no sexual dysfunction, fewer treatment-emergent adverse events than placebo in Phase 2. That matters for study design and for modeling the KOR system without the confounds that follow legacy compounds in this class.

Novelty

68

Mechanism promise

68

In-category differentiation

72

Evidence quality

56

Translational signal

44

Research bench value

68

Rationale Navacaprant represents best-in-class pharmacology within the KOR antagonist class, with a mechanistically coherent anhedonia signal in Phase 2 and genuine probe utility for stress-circuit biology, but the KOASTAL-1 null (p=0.993, identical 12.5-point reductions in both arms) meaningfully depresses translational scores and prevents placement in the novel-frontier tier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective, reversible kappa opioid receptor antagonist with no agonist activity at kappa, mu, or delta opioid receptors

A fluorinated quinoline-oxadiazole kappa opioid receptor antagonist discovered at Scripps Research and advanced through Phase 3 clinical trials for major depressive disorder, distinguished from earlier KOR antagonists by full receptor antagonism without mu or delta cross-reactivity, rapid reversibility, and a favorable tolerability profile in controlled clinical studies.

Abstract

Navacaprant (BTRX-335140, NMRA-140, CYM-53093) is a potent, highly selective, and reversible antagonist of the kappa opioid receptor (KOR) under clinical development for the treatment of major depressive disorder (MDD). The compound was discovered in collaboration between Scripps Research faculty members Hugh Rosen and Edward Roberts and was advanced through clinical development first by BlackThorn Therapeutics and subsequently by Neumora Therapeutics. Navacaprant blocks the KOR with an IC50 of 1.2 nanomolar in native ventral tegmental area dopamine neurons and 29 nanomolar in recombinant CHO-K1 cells, with approximately 300-fold selectivity over the mu opioid receptor and greater than 340-fold selectivity over the delta opioid receptor. The compound exhibits no detectable agonist activity at any opioid receptor subtype in vitro (EC50 greater than 10 micromolar) and no opioid agonist effects in vivo, including no alteration of extracellular dopamine in the nucleus accumbens at oral doses up to 100 mg/kg in rats. The pharmacological profile differentiates navacaprant from earlier KOR antagonists: unlike JDTic (which activates c-Jun N-terminal kinase and produced cardiac toxicity in humans), nor-binaltorphimine (which has an impractically long duration of action), and aticaprant (which partially blocks mu and delta opioid receptor responses in native tissue electrophysiology), navacaprant combines full KOR antagonism with rapid reversibility, clean selectivity, and no off-target opioid effects. In a Phase 1 program in healthy volunteers, navacaprant demonstrated favorable pharmacokinetics across single oral doses of 5 to 240 mg and multiple daily doses of 20 to 160 mg for 10 days, with good tolerability and no serious adverse events. A positron emission tomography receptor occupancy study confirmed brain KOR engagement, with a single 160 mg dose producing approximately 90 percent occupancy and pharmacokinetic-pharmacodynamic modeling projecting approximately 90 percent occupancy at steady state with 80 mg once daily. In a Phase 2a randomized, double-blind, placebo-controlled trial in 204 adults with MDD (Mathew et al. 2025), navacaprant 80 mg once daily for 8 weeks did not meet the primary endpoint in the full efficacy population (Hamilton Depression Rating Scale least-squares mean difference versus placebo of negative 1.7 points, p equals 0.121), but demonstrated statistically significant improvements in the moderate-to-severe MDD subgroup on both depressive symptoms and anhedonia as measured by the Snaith-Hamilton Pleasure Scale, with response rates of 45.5 percent versus 24.1 percent for placebo (number needed to treat equals 5) and remission rates of 26.1 percent versus 10.8 percent (number needed to treat equals 7). Fewer treatment-emergent adverse events occurred in the navacaprant group than in the placebo group, and no serious adverse events, weight gain, or sexual dysfunction were reported with navacaprant. In Phase 3, the KOASTAL-1 trial (n equals 383) failed to demonstrate separation from placebo on the Montgomery-Asberg Depression Rating Scale primary endpoint, with both treatment arms reporting identical 12.5-point reductions (p equals 0.993); exploratory subgroup analyses suggested a differential response in female participants. The KOASTAL-2 and KOASTAL-3 Phase 3 trials were paused for protocol modifications and are expected to report data in 2026. This monograph reviews the chemistry and structural pharmacology of navacaprant; the molecular pharmacology including receptor binding, selectivity, and electrophysiological characterization; the available pharmacokinetic data; the preclinical pharmacology in stress and cognitive models; the clinical evidence base including the Phase 2 and Phase 3 programs; sourcing and quality verification; handling considerations; stack interactions; adverse events; and a comparative assessment of five kappa opioid receptor candidates (aticaprant, buprenorphine-samidorphan, JDTic, nor-binaltorphimine, and PF-04455242) against navacaprant. The compound is investigational and is not approved by any regulatory authority. It is available as a research-grade preparation; investigators should obtain analytical confirmation of identity and purity on every lot.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1656Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 22, 2026
Roluperidone

Our opinion on this compoundNovel, promising

65/100

Novel sigma-2/5-HT2A profile targets schizophrenia negative symptoms without dopamine; FDA CRL tempers but doesn’t erase the signal

Look, the negative symptom problem in schizophrenia has been essentially unsolved for fifty years. Dopamine blockade handles positive symptoms reasonably well; it does almost nothing durable for avolition, alogia, and social withdrawal. Roluperidone is interesting precisely because it doesnt touch dopamine at all. No D1 through D5 binding, essentially. That alone makes it worth paying attention to.

The receptor story here is genuinely novel. The sigma-2 receptor sat in pharmacology textbooks as an orphan target for decades, and its molecular identity wasn’t confirmed until 2017, when Chu et al. established it as TMEM97, a transmembrane protein involved in calcium signaling, cholesterol homeostasis, and autophagy regulation. Roluperidone hits TMEM97 at Ki 8.19 nM, equipotent with its 5-HT2A affinity (Ki 7.53 nM). The 5-HT2A component also matters: chronic antagonism normalizes slow-wave sleep architecture, a deficit that tracks closely with negative symptom burden in schizophrenia. The mechanism isn’t just novel; theres a real biological rationale underneath it, and downstream effects on glutamatergic and dopaminergic tone via sigma-2 modulation add another layer worth investigating.

The clinical story is more complicated. Phase 2b (MIN-101C03, 244 patients) was genuinely clean: 32 mg and 64 mg doses both hit statistical significance on the PANSS negative subscale at 12 weeks, with effect sizes of 0.45 and 0.58. Those are respectable numbers for a notoriously hard-to-move symptom cluster. Phase 3 (EMERGENT-3, 513 patients) was murkier. The 64 mg arm hit nominal significance (p = 0.044, effect size 0.26) on the primary endpoint, plus a statistically significant improvement on the PSP social functioning scale. But the FDA issued a complete response letter in February 2024, citing insufficient evidence from a single adequate trial. Regulatory reality: Minerva got one positive phase 3, FDA wanted two. That’s a real setback, though it isn’t the same as a failed trial. The network intervention analysis identifying avolition as the directly targeted symptom is actually one of the more methodologically interesting findings in recent negative symptom research.

What we think is genuinely valuable here is the bench utility. If you’re studying sigma-2/TMEM97 biology in cortical or hippocampal neurons, roluperidone is currently the most clinically characterized selective antagonist available. The preclinical data on downstream neuroplasticity and neurotrophic effects are undercharacterized, and thats exactly what makes this a productive target for investigation. The compound lets you ask sigma-2 questions you simply can’t ask with anything else that has a human pharmacokinetic profile attached to it.

The main limitations are the modest phase 3 effect size, the FDA’s unresolved status, and incompletely mapped sigma-2 downstream biology. CYP2D6 metabolizer status adds a translational wrinkle. We wouldn’t call this a solved story. But the receptor angle is novel enough, and the clinical signal is real enough, that investigators in negative symptom neurobiology or nondopaminergic neuropsychiatric pharmacology should have roluperidone on their radar.

Novelty

65

Mechanism promise

72

In-category differentiation

70

Evidence quality

55

Translational signal

60

Research bench value

68

Rationale Roluperidone scores well on novelty and mechanism for its dopamine-free sigma-2/TMEM97 pharmacology in a historically undrugged indication, but modest phase 3 effect sizes and the FDA’s complete response letter limit evidence and translational scores; genuine bench utility as the most clinically characterized sigma-2 antagonist keeps it firmly in novel-promising territory.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Sigma-2 receptor antagonist and serotonin 5-HT2A receptor antagonist with alpha-1A adrenergic receptor antagonism

A cyclic amide derivative with equipotent nanomolar antagonism at sigma-2 and 5-HT2A receptors, developed by Minerva Neurosciences as monotherapy for the negative symptoms of schizophrenia and distinguished from conventional antipsychotics by the absence of dopaminergic receptor binding.

Abstract

Roluperidone (MIN-101, formerly MT-210 and CYR-101) is a cyclic amide (isoindolinone) derivative that combines high-affinity antagonism at the sigma-2 receptor (TMEM97; Ki 8.19 nM) and the serotonin 5-HT2A receptor (Ki 7.53 nM) with lower-affinity antagonism at alpha-1A adrenergic receptors (Ki 4.17 nM), while exhibiting essentially no binding at dopamine D1 through D5 receptors, muscarinic, cholinergic, or histaminergic receptors. This receptor binding profile distinguishes roluperidone from all marketed antipsychotics and underwrites a pharmacological rationale for addressing the negative symptoms of schizophrenia through nondopaminergic mechanisms. The sigma-2 receptor, identified in 2017 as the transmembrane protein TMEM97, is expressed at high density in cortical and hippocampal neurons and is implicated in calcium signaling, cholesterol homeostasis, autophagy, and the modulation of dopaminergic and glutamatergic neurotransmission. The 5-HT2A antagonist component promotes slow-wave sleep normalization, a deficit that is consistently documented in schizophrenia and that correlates with negative symptom severity. Roluperidone was originally synthesized by Mitsubishi Tanabe Pharma Corporation (designated MT-210), licensed through Cyrenaic Pharmaceuticals (CYR-101), and advanced through clinical development by Minerva Neurosciences (MIN-101). In a Phase 2b randomized, double-blind, placebo-controlled trial of 244 patients with stable schizophrenia and moderate-to-severe negative symptoms (MIN-101C03), roluperidone monotherapy at 32 mg/day and 64 mg/day produced statistically significant improvement on the PANSS negative symptom factor score at 12 weeks (effect sizes 0.45 and 0.58, respectively; both p < 0.025). In the subsequent Phase 3 trial (EMERGENT-3, NCT03397134, 513 patients), the 64 mg/day dose reached nominal statistical significance on the primary negative symptom endpoint in the modified intent-to-treat analysis (p = 0.044, effect size 0.26), with statistically significant improvements in social functioning on the Personal and Social Performance scale (p = 0.021, effect size 0.27) and a negative symptom responder rate of 39% versus 23% on placebo (p = 0.006). Network intervention analysis of both trials identified avolition as the directly targeted symptom, with improvements cascading across the broader negative symptom constellation. Pharmacokinetics are characterized by oral bioavailability of 73% to 81%, peak plasma concentration at approximately 3.5 hours, and a plasma elimination half-life of approximately 7 hours after a 64 mg dose, supporting once-daily administration. CYP2D6 is involved in metabolism, and poor or intermediate CYP2D6 metabolizers were excluded from the Phase 3 trial. Tolerability across both trials was notable for the absence of clinically meaningful weight gain, metabolic changes, extrapyramidal symptoms, or prolactin elevation; the principal safety signal was QTc interval prolongation leading to discontinuation of three patients at the 64 mg dose in the Phase 3 trial. Minerva Neurosciences filed a New Drug Application with the U.S. Food and Drug Administration in April 2023. The FDA issued a Complete Response Letter in February 2024, citing insufficient evidence of effectiveness from a single adequate trial, absence of data on concomitant antipsychotic administration, and the need for additional evidence of clinical meaningfulness. The compound remains in development as of the monograph date. This monograph documents the chemistry, dual-receptor pharmacology, pharmacokinetics, preclinical and clinical evidence base, safety profile, and a comparative assessment of five compounds in the negative symptom treatment space against roluperidone on five competency standards. The compound is investigational and is not approved by any regulatory authority for any indication.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1657Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 22, 2026
Iclepertin

Our opinion on this compoundNiche research probe

46/100

Best-in-class GlyT1 probe with real Phase II signal, sunk by decisive Phase III replication failure

Iclepertin (BI 425809) came out of Boehringer Ingelheim’s push to do the GlyT1 inhibition story properly. The mechanism rationale is real: block GlyT1 astrocytic reuptake, saturate the NMDA glycine-B co-agonist site, and you’re effectively turning up the gain on glutamatergic neurotransmission in circuits that NMDA hypofunction models have implicated in schizophrenia’s cognitive deficits for three decades. At 5.0 nM IC50 in SK-N-MC cells, the compound is genuinely potent, and the azabicyclo[3.1.0]hexane scaffold with its three defined stereocenters gives you selectivity you dont get from sarcosine or D-serine. Mechanistically, this is probably the cleanest GlyT1 probe the field has produced.

The Phase II result (NCT02832037) was the thing that made people pay attention. A standardized effect size of 0.34 on the MCCB composite at 10 mg isn’t a throwaway signal. Honestly, in a space where cognitive endpoints in schizophrenia almost never move, 0.34 is remarkable. The qEEG substudy showed target engagement consistent with the occupancy modeling. There was a dose-response that made pharmacological sense, tracking the inverted-U relationship the preclinical team had flagged early. We liked this compound going into Phase III.

And then the CONNEX programme landed. 1835 patients across three trials, well-powered, and the Phase II signal did not replicate. This is where the story gets genuinely complicated for the research community. The failure isn’t obviously interpretable as “the mechanism is wrong.” Bitopertin, Roche’s GlyT1 inhibitor, failed Phase III earlier, which should have been a warning sign. The open question now is whether the NMDA hypofunction/GlyT1 approach is fundamentally broken for CIAS, or whether both programmes had endpoint selection, patient stratification, and concomitant antipsychotic confounds that swamped a real but modest effect. The field hasn’t reached consensus, and thats actually an interesting scientific problem.

What we think now: as a clinical candidate for CIAS, iclepertin is done. But as a probe compound, it’s still the most potent and selective small-molecule GlyT1 inhibitor in the public literature, and any investigator working on glutamate biology, NMDA receptor pharmacology, or the synaptic glycine co-agonist system has legitimate reasons to reach for it. The inverted-U dose-response data is useful for bench work on its own terms. You can use this compound to interrogate GlyT1 occupancy thresholds in rodent cognitive models in ways sarcosine or D-serine simply don’t allow.

What we don’t like: two large Phase III failures for the same mechanistic class is a heavy prior against the clinical translation story. The path from GlyT1 occupancy to durable cognitive benefit in schizophrenia populations looks harder than the preclinical models ever suggested, and that’s a problem the whole glutamate field is still working through. Score reflects the probe value as real, the clinical value as spent.

Novelty

38

Mechanism promise

45

In-category differentiation

47

Evidence quality

62

Translational signal

35

Research bench value

55

Rationale Iclepertin is the most potent and selective small-molecule GlyT1 inhibitor available and produced the strongest Phase II CIAS signal in its class (ES 0.34 on MCCB), but the CONNEX Phase III programme across 1835 patients failed to replicate; it scores as a serious research probe with intact mechanistic rationale, but the translational path for the primary clinical indication is broken and the GlyT1/CIAS hypothesis is now two-for-two in Phase III failure.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective glycine transporter type 1 (GlyT1) inhibitor for glutamatergic NMDA receptor enhancement

A potent azabicyclo[3.1.0]hexane methanone GlyT1 inhibitor developed by Boehringer Ingelheim to normalize glutamatergic hypofunction in schizophrenia, distinguished by positive Phase II cognitive efficacy signals (standardized effect size 0.34 on MCCB at 10 mg) and subsequent failure to replicate in the 1835-patient Phase III CONNEX programme.

Abstract

Iclepertin (BI 425809) is a potent and selective inhibitor of glycine transporter type 1 (GlyT1) with an IC50 of 5.0 nanomolar in human SK-N-MC cells, developed by Boehringer Ingelheim for the treatment of cognitive impairment associated with schizophrenia (CIAS). The compound is an orally bioavailable azabicyclo[3.1.0]hexane methanone bearing two trifluoromethyl groups and a methylsulfonyl substituent, with three defined stereocenters and a molecular weight of 512.42 g/mol. By blocking the reuptake of glycine from the synaptic cleft into astrocytes and presynaptic terminals, iclepertin increases synaptic glycine concentration at the glycine-B co-agonist site of the N-methyl-D-aspartate (NMDA) receptor, thereby enhancing glutamatergic neurotransmission. This mechanism addresses the NMDA receptor hypofunction hypothesis of schizophrenia, which posits that reduced glutamatergic signaling contributes to the cognitive deficits observed in the disorder.

Pharmacokinetically, iclepertin exhibits a terminal half-life of 34 to 59 hours, supporting once-daily oral dosing with steady-state conditions achieved by day 6. Oral bioavailability is approximately 72 percent for a 25 mg tablet under fasted conditions. The compound is metabolized predominantly (90 percent or greater) by cytochrome P450 3A4, rendering it sensitive to strong CYP3A4 inhibitors (approximately 6-fold AUC increase with itraconazole) and inducers (approximately 90 percent AUC reduction with rifampicin). In Phase I studies, oral administration of 10 mg produced a dose-dependent approximately 50 percent increase in cerebrospinal fluid glycine levels, confirming central target engagement.

The Phase II clinical programme produced divergent results across indications. In a 509-patient randomized, double-blind, placebo-controlled trial in schizophrenia (NCT02832037), iclepertin at 10 mg once daily for 12 weeks produced a statistically significant improvement on the MATRICS Consensus Cognitive Battery overall composite T-score, with an adjusted mean difference of 1.98 points and a standardized effect size of 0.34 versus placebo. However, a parallel 610-patient Phase II trial in mild-to-moderate Alzheimer’s disease dementia (NCT02788513) failed to demonstrate any dose-response relationship on the ADAS-Cog11 primary endpoint. A subsequent Phase II trial combining iclepertin with computerized cognitive training (NCT03859973, n=200) also failed to meet its primary endpoint. The compound received United States Food and Drug Administration Breakthrough Therapy Designation for CIAS in May 2021. In January 2025, Boehringer Ingelheim reported that the Phase III CONNEX programme, comprising three replicate randomized controlled trials enrolling 1835 patients across 338 sites in 41 countries with 26 weeks of treatment at 10 mg once daily, failed to meet its primary or key secondary endpoints (pooled MCCB adjusted mean difference 0.127, 95 percent confidence interval negative 0.396 to 0.650, p=0.63). Iclepertin was well tolerated across all trials, with adverse event rates numerically similar to or lower than placebo. The compound is not approved in any jurisdiction.

This monograph reviews the chemistry and synthesis of iclepertin; the molecular pharmacology of GlyT1 inhibition and the NMDA receptor enhancement mechanism; the comprehensive pharmacokinetic characterization including CYP3A4 drug-drug interactions; preclinical efficacy in MK-801 deficit and social recognition models; the complete clinical evidence base across schizophrenia, Alzheimer’s disease, and cognitive training paradigms; reconstitution, sourcing, and handling considerations; adverse event and safety signals; and a comparative assessment of five alternative NMDA-enhancing or GlyT1-targeting compounds (bitopertin, sarcosine, D-serine, PF-03463275, luvadaxistat) against iclepertin on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1648Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 22, 2026
Aficamten

Our opinion on this compoundEstablished, active research

70/100

Second-gen cardiac myosin inhibitor with FDA approval, a distinct allosteric site, and genuinely rigorous phase 3 evidence in HCM

Look, the cardiac myosin inhibitor class is one of the genuinely new things that happened in cardiovascular pharmacology in the last decade. The idea of intervening directly at the sarcomere rather than working upstream through adrenergic receptors or calcium channels represents a real conceptual break from fifty years of HCM management. Aficamten sits in that class as the second approved agent, but its binding site is not just a pharmacokinetic tweak on mavacamten: it overlaps with the blebbistatin pocket rather than mavacamten’s canonical site, and it slows phosphate release from the myosin ATPase cycle to rates slower than the conventional super-relaxed state. Thats a meaningful mechanistic distinction, not a minor structural refinement.

What we like here is the evidence architecture. The SEQUOIA-HCM pivotal trial is a proper Phase 3 RCT with hard hemodynamic and functional endpoints, and MAPLE-HCM adds the direct head-to-head comparison with metoprolol that the field had been asking for since mavacamten approval. ACACIA-HCM extends the question into non-obstructive disease, and FOREST-HCM provides the long-term extension read. For a compound still under two years old as an approved drug, that is a dense and methodologically disciplined program. FDA sign-off in December 2025 reflects a trial package that survived real regulatory scrutiny.

The differentiation story is genuine but not yet decisive. Aficamten’s engineered PK profile reduces the CYP2D6 variability that makes mavacamten titration complicated in real-world polypharmacy patients. The faster off-kinetics are clinically relevant for a drug that requires LVEF monitoring and rapid dose adjustment. But we’re honest that two allosteric cardiac myosin inhibitors competing for the same indication with overlapping mechanisms leaves the superiority question open. FOREST-HCM will help close it. Right now, aficamten is clearly best-in-class on pharmacokinetic manageability; it’s not yet clearly best-in-class on outcomes.

For bench investigators, the blebbistatin-pocket binding gives aficamten probe value that mavacamten does not replicate exactly. If you’re studying pre-power-stroke state stabilization or trying to dissect myosin ATPase kinetics in disease models, having two chemically distinct agents at different allosteric sites is genuinely useful. The feline spontaneous HCM model work also provides a translational bridge that transgenic-only programs don’t, which matters for groups working in naturally occurring disease.

Honestly, what keeps the score at 70 rather than climbing into the 80s is scale and novelty ceiling. HCM affects roughly 1 in 500 people, which is not the metabolic field where the GLP-1 agents are reshaping population-level outcomes. The mechanism, while elegant, is now second-in-class in its own category. And the evidence base, strong as it is, comes from a single-developer program in a single indication. Aficamten is a serious compound with serious data, best-in-class on several dimensions. It is not a field-reshaping discovery; it’s the second, better-engineered answer to a real clinical problem.

Novelty

60

Mechanism promise

78

In-category differentiation

65

Evidence quality

80

Translational signal

78

Research bench value

60

Rationale Aficamten earns strong mechanism and evidence scores as the only second approved sarcomere-level agent in HCM, with a binding site distinct from mavacamten and multiple Phase 3 programs culminating in December 2025 FDA approval; novelty is tempered by being second-in-class in a narrow indication and differentiation from mavacamten remains partially unresolved in long-term extension data.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective small-molecule allosteric inhibitor of cardiac beta-myosin heavy chain (MYH7) ATPase activity

A next-generation cardiac myosin inhibitor developed by Cytokinetics as CK-3773274, engineered for optimized pharmacokinetic properties relative to mavacamten, approved by the United States Food and Drug Administration in December 2025 for the treatment of symptomatic obstructive hypertrophic cardiomyopathy under the trade name MYQORZO.

Abstract

Aficamten (CK-3773274, trade name MYQORZO) is a selective, allosteric, reversible small-molecule inhibitor of cardiac myosin motor activity developed by Cytokinetics, Inc. for the treatment of hypertrophic cardiomyopathy (HCM). The compound reduces myocardial contractility by stabilizing a weak actin-binding, pre-power-stroke state of the beta-cardiac myosin head, thereby decreasing the number of functional myosin cross-bridges available during each cardiac cycle and attenuating the left ventricular outflow tract (LVOT) obstruction that drives symptoms in obstructive HCM. Aficamten binds to an allosteric site between the upper 50 kDa and lower 50 kDa subdomains of the myosin catalytic domain, overlapping with the blebbistatin binding pocket but distinct from the mavacamten binding site, and dramatically slows phosphate release from the myosin ATPase cycle to a rate slower than the conventional super-relaxed state.

The compound was engineered to address pharmacokinetic limitations of mavacamten, the first-in-class cardiac myosin inhibitor. Aficamten achieves a plasma elimination half-life of approximately 75 to 100 hours (compared to 7 to 9 days for mavacamten), reaches steady-state plasma concentrations within approximately 2 weeks of daily dosing (compared to approximately 6 weeks for mavacamten), demonstrates reversibility of pharmacodynamic effects within 24 to 48 hours, exhibits a shallow exposure-response relationship that widens the therapeutic window, and is metabolized by multiple cytochrome P450 enzymes (CYP2C9, CYP3A4, CYP2D6, CYP2C19) rather than predominantly by the polymorphic CYP2C19, thereby reducing the drug-drug interaction burden and eliminating the requirement for CYP metabolizer genotyping.

Clinical development of aficamten has proceeded through a comprehensive program. The Phase 1 dose-escalation study in 102 healthy participants demonstrated dose-proportional pharmacokinetics, dose-dependent reductions in left ventricular ejection fraction (LVEF), and favorable tolerability with no serious adverse events. The Phase 2 REDWOOD-HCM trial in patients with symptomatic obstructive HCM demonstrated statistically significant reductions in resting and post-Valsalva LVOT gradients, with 78.6 to 92.9 percent of patients achieving target gradient reduction at 10 weeks. The pivotal Phase 3 SEQUOIA-HCM trial randomized 282 patients with symptomatic obstructive HCM to aficamten or placebo for 24 weeks and met its primary endpoint of improved peak oxygen uptake (pVO2), with a least-squares mean difference of 1.74 mL/kg/min (p = 0.000002), along with statistically significant improvements in all 10 prespecified secondary endpoints including NYHA functional class, Kansas City Cardiomyopathy Questionnaire scores, and LVOT gradient reduction. The Phase 3 MAPLE-HCM trial demonstrated superiority of aficamten monotherapy over metoprolol monotherapy, with a pVO2 least-squares mean difference of 2.3 mL/kg/min (p < 0.0001). The Phase 3 ACACIA-HCM trial in 516 patients with non-obstructive HCM met both dual primary endpoints for symptom burden and exercise capacity improvement.

The United States Food and Drug Administration approved aficamten on December 19, 2025, for the treatment of adults with symptomatic obstructive HCM to improve functional capacity and symptoms, marketed as MYQORZO. The approval includes a boxed warning regarding the risk of heart failure due to systolic dysfunction and a Risk Evaluation and Mitigation Strategy (REMS) requiring echocardiographic monitoring. The principal adverse reaction observed at greater than 5 percent incidence above placebo was hypertension (8 percent versus 2 percent). LVEF reduction below 50 percent occurred in 3.5 percent of aficamten-treated patients in SEQUOIA-HCM compared to 0.7 percent on placebo; all instances were mild, reversible, and not associated with clinical heart failure events. This monograph reviews the chemistry, mechanism, pharmacokinetics, preclinical and clinical evidence, safety profile, handling considerations, and comparative assessment of aficamten against five alternative agents for the management of hypertrophic cardiomyopathy.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1622Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 21, 2026

←Previous Page

1 2 3 4 5 6 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.